| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(9 years from now) | |
Belsomra is owned by Merck Sharp Dohme.
Belsomra contains Suvorexant.
Belsomra has a total of 2 drug patents out of which 0 drug patents have expired.
Belsomra was authorised for market use on 13 August, 2014.
Belsomra is available in tablet;oral dosage forms.
Belsomra can be used as treatment of insomnia.
Drug patent challenges can be filed against Belsomra from 13 August, 2018.
The generics of Belsomra are possible to be released after 29 May, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-253) | Jan 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
More Information on Dosage
BELSOMRA family patents
